Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Colorcon
Boehringer Ingelheim
Dow
Merck

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Sirna-027

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Sirna-027?

Sirna-027 is an investigational drug.

There have been 22 clinical trials for Sirna-027. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2016.

The most common disease conditions in clinical trials are Pancreatic Neoplasms, Nails, Malformed, and Neovascularization, Pathologic. The leading clinical trial sponsors are National Cancer Institute (NCI), Dicerna Pharmaceuticals, Inc., and Nitto Denko Corporation.

There are three US patents protecting this investigational drug and two hundred and fifty-five international patents.

Recent Clinical Trials for Sirna-027
TitleSponsorPhase
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D MutationNational Cancer Institute (NCI)Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D MutationM.D. Anderson Cancer CenterPhase 1
Genomic Responses of Human Immune and Non-Immune Cells to GlucocorticoidsNational Institute of Allergy and Infectious Diseases (NIAID)Phase 1

See all Sirna-027 clinical trials

Clinical Trial Summary for Sirna-027

Top disease conditions for Sirna-027
Top clinical trial sponsors for Sirna-027

See all Sirna-027 clinical trials

US Patents for Sirna-027

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sirna-027   Start Trial Recombinant vectors Tocagen Inc. (San Diego, CA)   Start Trial
Sirna-027   Start Trial Compositions and methods to control angiogenesis with cupredoxins The Board of Trustees of the University of Illinois (Urbana, IL)   Start Trial
Sirna-027   Start Trial Recombinant vectors Tocagen Inc. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sirna-027

Drugname Country Document Number Estimated Expiration Related US Patent
Sirna-027 Australia 2009303690 2028-09-26   Start Trial
Sirna-027 Brazil PI0919113 2028-09-26   Start Trial
Sirna-027 Canada 2738472 2028-09-26   Start Trial
Sirna-027 China 102227501 2028-09-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Medtronic
Dow
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.